- Home
- Publications
- Publication Search
- Publication Details
Title
Novel pharmacological interventions for diabetic kidney disease
Authors
Keywords
-
Journal
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-28
DOI
10.1097/mnh.0000000000000935
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
- (2023) Peter Rossing et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
- (2023) Merlin C. Thomas et al. Cell Metabolism
- Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
- (2023) Hertzel C. Gerstein et al. CIRCULATION
- Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies
- (2023) Anna K. Forbes et al. DIABETES OBESITY & METABOLISM
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial
- (2023) Darren K. McGuire et al. DIABETES OBESITY & METABOLISM
- Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure
- (2023) Safia Chatur et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Oxidative stress as a culprit in diabetic kidney disease
- (2023) Sensen Su et al. LIFE SCIENCES
- The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis
- (2023) Reid Whitlock et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
- (2023) Merlin C. Thomas et al. Endocrine Connections
- Inhibition of clonal expansion of parietal epithelial cells and crescent–podocyte transition in severe glomerulonephritis: on the way to targeted therapy?
- (2023) Ilay Berke Mentese et al. Clinical Kidney Journal
- Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
- (2023) Sandra C. Naaman et al. DIABETES CARE
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
- (2023) Julio Rosenstock et al. LANCET
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- (2023) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
- (2022) Alexander Peikert et al. EUROPEAN JOURNAL OF HEART FAILURE
- A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
- (2022) Allen Yan Lun Liu et al. Clinical Kidney Journal
- Research progress of endothelial‐mesenchymal transition in diabetic kidney disease
- (2022) Ying Chen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
- (2022) Fenghui Zhao et al. Nature Communications
- Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
- (2022) Ellen Conceição-Furber et al. Frontiers in Endocrinology
- Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
- (2022) Jennifer B Green et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice
- (2022) Maria Elena Melica et al. Science Translational Medicine
- Albiglutide in patients with type 2 diabetes and heart failure: a post‐hoc analysis from Harmony Outcomes
- (2022) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related molecules
- (2022) Jiali Tang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
- (2022) Masaomi Nangaku et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cellular phenotypic transitions in diabetic nephropathy: An update
- (2022) Yiling Cao et al. Frontiers in Pharmacology
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
- (2022) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives
- (2022) Daniela Maria Tanase et al. Biomolecules
- Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
- (2022) Yaofu Zhang et al. Cardiovascular Diabetology
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
- (2022) Colin Baigent et al. LANCET
- Empagliflozin in Patients with Chronic Kidney Disease
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
- (2022) Mason W. Freeman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tirzepatide and prevention of chronic kidney disease
- (2022) Catalina Bosch et al. Clinical Kidney Journal
- Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
- (2021) Hiddo J L Heerspink et al. EUROPEAN HEART JOURNAL
- Effects of metabolic memory on inflammation and fibrosis associated with diabetic kidney disease: an epigenetic perspective
- (2021) Wen Zheng et al. Clinical Epigenetics
- A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
- (2021) Hiddo JL. Heerspink et al. KIDNEY INTERNATIONAL
- Potential cardiorenal benefits of efpeglenatide in diabetes
- (2021) Jacques Ma et al. Nature Reviews Nephrology
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
- (2021) Carolyn S.P. Lam et al. CIRCULATION
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- NOX inhibition: Pre-clinical and clinical studies in diabetic complications
- (2020) Sofia Urner et al. ANTIOXIDANTS & REDOX SIGNALING
- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2020) Boris Bikbov et al. LANCET
- Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan
- (2020) Alysha M. De Livera et al. Trials
- Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
- (2020) Rosario Pivonello et al. Lancet Diabetes & Endocrinology
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- (2020) Michael G. Shlipak et al. KIDNEY INTERNATIONAL
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
- (2020) Ashish Sarraju et al. AMERICAN HEART JOURNAL
- New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction
- (2020) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
- (2019) Mitsuo Kato et al. Nature Reviews Nephrology
- Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Selonsertib in Patients with Diabetic Kidney Disease
- (2019) Glenn M. Chertow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
- (2019) M. Angelyn Bethel et al. DIABETES CARE
- On the mechanism of calcium‐dependent activation of NADPH oxidase 5 (NOX5)
- (2019) Elisa Millana Fañanás et al. FEBS Journal
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- The Global Epidemiology of Diabetes and Kidney Disease
- (2018) Digsu N. Koye et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial
- (2018) Richard Haynes et al. CIRCULATION
- The Role of Cannabinoid Receptors in Renal Diseases
- (2018) Helene Francois et al. CURRENT MEDICINAL CHEMISTRY
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Targeting the CDA1/CDA1BP1 Axis Retards Renal Fibrosis in Experimental Diabetic Nephropathy
- (2018) Zhonglin Chai et al. DIABETES
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes and Kidney Disease: Role of Oxidative Stress
- (2016) Jay C. Jha et al. ANTIOXIDANTS & REDOX SIGNALING
- Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)Novelty and Significance
- (2016) Katrijn Bogman et al. HYPERTENSION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials
- (2015) Chirag Bavishi et al. EUROPEAN HEART JOURNAL
- Lack of glucagon receptor signaling and its implications beyond glucose homeostasis
- (2015) M. J. Charron et al. JOURNAL OF ENDOCRINOLOGY
- Novel RAAS agonists and antagonists: clinical applications and controversies
- (2015) Cesar A. Romero et al. Nature Reviews Endocrinology
- Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
- (2015) Merlin C. Thomas et al. Nature Reviews Nephrology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetic kidney disease
- (2015) Merlin C. Thomas et al. Nature Reviews Disease Primers
- MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction
- (2014) C.-L. Lin et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Deletion of Cell Division Autoantigen 1 Retards Diabetes-Associated Renal Injury
- (2013) Z. Chai et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b
- (2013) Bo Wang et al. KIDNEY INTERNATIONAL
- MicroRNA-29b Inhibits Diabetic Nephropathy in db/db Mice
- (2013) Hai-Yong Chen et al. MOLECULAR THERAPY
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinguishing Hyperglycemic Changes by Set7 in Vascular Endothelial Cells
- (2012) Jun Okabe et al. CIRCULATION RESEARCH
- Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy
- (2012) Andrew S. Bomback et al. Journal of the American Society of Hypertension
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
- (2011) Pablo E. Pergola et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy
- (2010) F. Barutta et al. DIABETES
- Avosentan for Overt Diabetic Nephropathy
- (2010) J. F.E. Mann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy
- (2010) Yugang Tu et al. KIDNEY INTERNATIONAL
- Neuropsychiatric adverse effects signal the end of the line for rimonabant
- (2010) Alexandra King Nature Reviews Cardiology
- Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions
- (2009) T M Fong et al. INTERNATIONAL JOURNAL OF OBESITY
- Role of the Histone H3 Lysine 4 Methyltransferase, SET7/9, in the Regulation of NF-κB-dependent Inflammatory Genes
- (2008) Yan Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started